A peroxisome proliferator-activated receptor-γ agonist and the p53 rescue drug CP-31398 inhibit the spontaneous immortalization of breast epithelial cells

Brittney Shea Herbert, Virginia P. Pearce, Linda S. Hynan, Denise M. LaRue, Woodring E. Wright, Levy Kopelovich, Jerry W. Shay

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Cell immortalization is a critical and rate-limiting step in cancer progression. Agents that inhibit cell immortalization may have utility for novel molecular chemopreventive strategies. Preimmortal breast epithelial cells derived from a patient with the Li-Fraumeni Syndrome (LFS) can spontaneously immortalize in vitro at a measurable and reproducible frequency. In the present study, these cells were treated in vitro with low (nM) concentrations of potential and otherwise clinically validated chemopreventive agents, including several nonsteroidal anti-inflammatory drugs, rosiglitazone maleate, and the p53 rescue drug CP-31398. Rosiglitazone maleate (P < 0.05) and CP-31398 (P < 0.05) significantly inhibited the frequency of spontaneous immortalization of LFS breast epithelial cells compared with untreated controls. Nonsteroidal anti-inflammatory drugs, including specific cyclooxengenase-2 inhibitors, only moderately inhibited the spontaneous immortalization of preimmortal LFS breast epithelial cells. The significant effects of the p53 rescue drug CP-31398 correlated with the increase in cellular death induced by telomere shortening-induced DNA damage signals, including increases in p53 and p21 protein levels. Because immortalization is one step in cancer progression, these studies show the potential usefulness of a cell-based model system to screen the effects of known and potentially novel chemopreventive agents, using cell immortalization as an end point.

Original languageEnglish (US)
Pages (from-to)1914-1919
Number of pages6
JournalCancer Research
Volume63
Issue number8
StatePublished - Apr 15 2003

Fingerprint

Drug Repositioning
Peroxisome Proliferator-Activated Receptors
rosiglitazone
Li-Fraumeni Syndrome
Breast
Epithelial Cells
Anti-Inflammatory Agents
Telomere Shortening
Pharmaceutical Preparations
DNA Damage
Neoplasms
CP 31398
Proteins

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

A peroxisome proliferator-activated receptor-γ agonist and the p53 rescue drug CP-31398 inhibit the spontaneous immortalization of breast epithelial cells. / Herbert, Brittney Shea; Pearce, Virginia P.; Hynan, Linda S.; LaRue, Denise M.; Wright, Woodring E.; Kopelovich, Levy; Shay, Jerry W.

In: Cancer Research, Vol. 63, No. 8, 15.04.2003, p. 1914-1919.

Research output: Contribution to journalArticle

@article{0f7d67a0ccad45998a35b926d84d5d03,
title = "A peroxisome proliferator-activated receptor-γ agonist and the p53 rescue drug CP-31398 inhibit the spontaneous immortalization of breast epithelial cells",
abstract = "Cell immortalization is a critical and rate-limiting step in cancer progression. Agents that inhibit cell immortalization may have utility for novel molecular chemopreventive strategies. Preimmortal breast epithelial cells derived from a patient with the Li-Fraumeni Syndrome (LFS) can spontaneously immortalize in vitro at a measurable and reproducible frequency. In the present study, these cells were treated in vitro with low (nM) concentrations of potential and otherwise clinically validated chemopreventive agents, including several nonsteroidal anti-inflammatory drugs, rosiglitazone maleate, and the p53 rescue drug CP-31398. Rosiglitazone maleate (P < 0.05) and CP-31398 (P < 0.05) significantly inhibited the frequency of spontaneous immortalization of LFS breast epithelial cells compared with untreated controls. Nonsteroidal anti-inflammatory drugs, including specific cyclooxengenase-2 inhibitors, only moderately inhibited the spontaneous immortalization of preimmortal LFS breast epithelial cells. The significant effects of the p53 rescue drug CP-31398 correlated with the increase in cellular death induced by telomere shortening-induced DNA damage signals, including increases in p53 and p21 protein levels. Because immortalization is one step in cancer progression, these studies show the potential usefulness of a cell-based model system to screen the effects of known and potentially novel chemopreventive agents, using cell immortalization as an end point.",
author = "Herbert, {Brittney Shea} and Pearce, {Virginia P.} and Hynan, {Linda S.} and LaRue, {Denise M.} and Wright, {Woodring E.} and Levy Kopelovich and Shay, {Jerry W.}",
year = "2003",
month = "4",
day = "15",
language = "English (US)",
volume = "63",
pages = "1914--1919",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "8",

}

TY - JOUR

T1 - A peroxisome proliferator-activated receptor-γ agonist and the p53 rescue drug CP-31398 inhibit the spontaneous immortalization of breast epithelial cells

AU - Herbert, Brittney Shea

AU - Pearce, Virginia P.

AU - Hynan, Linda S.

AU - LaRue, Denise M.

AU - Wright, Woodring E.

AU - Kopelovich, Levy

AU - Shay, Jerry W.

PY - 2003/4/15

Y1 - 2003/4/15

N2 - Cell immortalization is a critical and rate-limiting step in cancer progression. Agents that inhibit cell immortalization may have utility for novel molecular chemopreventive strategies. Preimmortal breast epithelial cells derived from a patient with the Li-Fraumeni Syndrome (LFS) can spontaneously immortalize in vitro at a measurable and reproducible frequency. In the present study, these cells were treated in vitro with low (nM) concentrations of potential and otherwise clinically validated chemopreventive agents, including several nonsteroidal anti-inflammatory drugs, rosiglitazone maleate, and the p53 rescue drug CP-31398. Rosiglitazone maleate (P < 0.05) and CP-31398 (P < 0.05) significantly inhibited the frequency of spontaneous immortalization of LFS breast epithelial cells compared with untreated controls. Nonsteroidal anti-inflammatory drugs, including specific cyclooxengenase-2 inhibitors, only moderately inhibited the spontaneous immortalization of preimmortal LFS breast epithelial cells. The significant effects of the p53 rescue drug CP-31398 correlated with the increase in cellular death induced by telomere shortening-induced DNA damage signals, including increases in p53 and p21 protein levels. Because immortalization is one step in cancer progression, these studies show the potential usefulness of a cell-based model system to screen the effects of known and potentially novel chemopreventive agents, using cell immortalization as an end point.

AB - Cell immortalization is a critical and rate-limiting step in cancer progression. Agents that inhibit cell immortalization may have utility for novel molecular chemopreventive strategies. Preimmortal breast epithelial cells derived from a patient with the Li-Fraumeni Syndrome (LFS) can spontaneously immortalize in vitro at a measurable and reproducible frequency. In the present study, these cells were treated in vitro with low (nM) concentrations of potential and otherwise clinically validated chemopreventive agents, including several nonsteroidal anti-inflammatory drugs, rosiglitazone maleate, and the p53 rescue drug CP-31398. Rosiglitazone maleate (P < 0.05) and CP-31398 (P < 0.05) significantly inhibited the frequency of spontaneous immortalization of LFS breast epithelial cells compared with untreated controls. Nonsteroidal anti-inflammatory drugs, including specific cyclooxengenase-2 inhibitors, only moderately inhibited the spontaneous immortalization of preimmortal LFS breast epithelial cells. The significant effects of the p53 rescue drug CP-31398 correlated with the increase in cellular death induced by telomere shortening-induced DNA damage signals, including increases in p53 and p21 protein levels. Because immortalization is one step in cancer progression, these studies show the potential usefulness of a cell-based model system to screen the effects of known and potentially novel chemopreventive agents, using cell immortalization as an end point.

UR - http://www.scopus.com/inward/record.url?scp=0037447175&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037447175&partnerID=8YFLogxK

M3 - Article

VL - 63

SP - 1914

EP - 1919

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 8

ER -